US Patent Issued to HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT on Feb. 10 for "Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms" (Israeli Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,366, issued on Feb. 10, was assigned to HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem).

"Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms" was invented by Simona Glasberg (Jerusalem), David Polak (Jerusalem) and Shani Avniel Polak (Jerusalem).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are methods of treatment, compositions and kits comprising endocannabinoid receptor (ECR) antagonist and an mTOR inhibitor for treating neoplasm in a subject in need thereof, and reducing drug resistance to standard treatment."

The patent was filed on May 17, 2023, under Application No. 18...